MedPath

The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction

Phase 4
Completed
Conditions
Acute Myocardial Infarction
Interventions
Registration Number
NCT00611169
Lead Sponsor
Samsung Medical Center
Brief Summary

The purpose of this study to investigate whether the administration of high-dose tirofiban before primary PCI could reduce myocardial infarct size, using analysis of contrast-enhanced magnetic resonance imaging.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
  • ST-segment elevation more than 1 mm in two or more contiguous leads or presumably a new-onset left bundle branch blockage
Read More
Exclusion Criteria
  • hemodynamic instability
  • history of MI
  • old age > 80years
  • Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1tirofibanAspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
Primary Outcome Measures
NameTimeMethod
Infarct size and its transmural extent using MRIwithin the first 30 days after index procedure
Secondary Outcome Measures
NameTimeMethod
pre-PCI thrombolysis in myocardial infarction grade, post-PCI myocardial blush grade, ST-segment resolution on electrocardiography, and left ventricular ejection fraction on echocardiographyat 6 month after index procedure
© Copyright 2025. All Rights Reserved by MedPath